Syntekabio, an AI new drug development specialist company (CEO Jeong Jong-seon), announced on the 9th that it held a company-wide workshop at the Daejeon ABS Center, the foundation of its full-cycle AI new drug development platform.
A company official stated, “This workshop, attended by all employees including CEO Jeong Jong-seon and newly appointed Chief Operating Officer Yong Min-je, reflected the entire staff’s determination to make 2025 the inaugural year of the company’s leap forward.”
The ‘Co-Location’ business model, which utilizes the ABS Center recently certified with the highest grade, Platinum, for green data centers, is expected not only to secure sales in a short period and serve as the company’s cash cow but also to become a communication hub for expanding full-cycle AI new drug development solutions in the future.
Moreover, pharmaceutical and bio companies participating in ‘Co-Location,’ as well as potential clients facing difficulties operating high-performance server equipment, can receive consulting on operational know-how such as protein simulation, machine learning, and cloud supercomputing at the bio-specialized ABS Center, creating many mutual synergy factors.
In particular, with the official launch of the cloud-based next-generation convergent language model AI new drug development SaaS (Software as a Service), which the company has long devoted itself to developing, imminent, the workshop served as an opportunity to confirm the final success through various opinions and discussions on the last technical inspections and commercialization strategies.
‘SaaS’ is a next-generation convergent AI language model-based platform set to infinitely generate effective substances for disease targets, based on 200 million protein structures predicted by Google AlphaFold, all known 3D structure bank data, and a compound library of over 10 billion compounds.
Jeong Jong-seon, CEO of Syntekabio, said, “Through the successful commercialization of the ‘Co-Location’ service and ‘SaaS’ this year, we aim to make this the inaugural year of a leap forward by securing customer trust and sales for the full-cycle AI new drug development platform service. Furthermore, it became an opportunity to reaffirm the passion and determination of all employees to soar as a global AI new drug development platform company.”
In fact, discovering candidate substances for targets with unmet needs and extremely difficult development is the only way to create real added value, and this is the environment most global pharmaceutical and bio companies are challenging. Syntekabio’s language model is specialized in solving these problems, and furthermore, only an AI new drug development platform that can infinitely generate candidate substances until effective substances emerge and quickly synthesize and purchase them at low cost can be the sole means in the future.
Finally, the event concluded by honoring the long-term employees for their dedication and hard work.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
